Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real-world setting in Taiwan.
Kun-Hung ChenKo-Jen LiYao-Fan FangSong-Chou HsiehYing-Chou ChenChyou-Shen LeeShue-Fen LuoTien-Tsai ChengWen Chan TsaiYu-Chen LoJoung-Liang LanPublished in: International journal of rheumatic diseases (2024)
The 24-month retention rate of abatacept was 59.9%; abatacept was associated with improved clinical outcomes and was well-tolerated in the real-world setting in Taiwan.